Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LORATADINE REDIDOSE.
KETOTIFEN FUMARATE vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
10 mg orally once daily
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine